Eukaryotic translation initiation factor eIF5 promotes the accuracy of start codon recognition by regulating $P_i$ release and conformational transitions of the preinitiation complex

Adesh K. Saini$^{1,2,*}$, Jagpreet S. Nanda$^{3,†}$, Pilar Martin-Marcos$^1$, Jinsheng Dong$^1$, Fan Zhang$^1$, Monika Bhardwaj$^2$, Jon R. Lorsch$^3,*$ and Alan G. Hinnebusch$^1,*$

$^1$Laboratory of Gene Regulation and Development, Eunice K. Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA, $^2$Shoolini University of Biotechnology and Management Sciences, Department of Biotechnology, Bajhol, Solan, Himachal Pradesh 173229, India and $^3$Laboratory on the Mechanism and Regulation of Protein Synthesis, Eunice K. Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA

Received April 3, 2014; Revised June 9, 2014; Accepted July 8, 2014

**ABSTRACT**

eIF5 is the GTPase activating protein (GAP) for the eIF2-GTP-Met-tRNA$_{\text{Met}}$ ternary complex with a critical role in initiation codon selection. Previous work suggested that the eIF5 mutation G31R/SUI5 elevates initiation at UUG codons by increasing GAP function. Subsequent work implicated eIF5 in rearrangement of the preinitiation complex (PIC) from an open, scanning conformation to a closed state at AUG codons, from which $P_i$ is released from eIF2-GDP-$P_i$. To identify eIF5 functions crucial for accurate initiation, we investigated the consequences of G31R on GTP hydrolysis and $P_i$ release, and the effects of intragenic G31R suppressors on these reactions, and on the partitioning of PICs between open and closed states. eIF5-G31R altered regulation of $P_i$ release, accelerating it at UUG while decreasing it at AUG codons, consistent with its ability to stabilize the closed complex at UUG. Suppressor G62S mitigates both defects of G31R, accounting for its efficient suppression of UUG initiation in G31R, G62S cells; however suppressor M18V impairs GTP hydrolysis with little effect on PIC conformation. The strong defect in GTP hydrolysis conferred by M18V likely explains its broad suppression of Sui$^{-}$ mutations in numerous factors. We conclude that both of eIF5’s functions, regulating $P_i$ release and stabilizing the closed PIC conformation, contribute to stringent AUG selection in vivo.

**INTRODUCTION**

In translation initiation by the scanning mechanism, the small (40S) ribosomal subunit harboring initiator methionyl tRNA (Met-tRNA$_{\text{Met}}$) bound to eIF2-GTP in a ternary complex (TC) attaches near the capped 5’ end of the mRNA and scans the leader for an AUG triplet in optimal sequence context (reviewed in (1,2)). According to our current model (Figure 1A), eIF1 and eIF1A promote an ‘open’ conformation of the 40S subunit that is competent for binding the TC in a metastable state (P$_{\text{OUT}}$) that allows the Met-tRNA$_{\text{Met}}$ to sample successive triplets entering the P site for complementarity to the anticodon triplet. The GTPase activating protein (GAP) eIF5 stimulates Guanosine-5’-triphosphate (GTP) hydrolysis by the TC, but completion of the reaction with release of $P_i$ is blocked by eIF1 in the scanning preinitiation complex (PIC). Base-pairing of Met-tRNA$_{\text{Met}}$ with an AUG triplet evokes a rearrangement of factors in the PIC, including displacement of eIF1 and the C-terminal tail (CTT) of eIF1A from their locations near the P site, and movement of the eIF1A CTT toward the GAP domain of eIF5. These rearrangements enable dissociation of eIF1 from the 40S subunit, evoking a closed, scanning-arrested conformation of the 40S subunit, $P_i$ release from eIF2-GDP, and tighter binding of Met-tRNA$_{\text{Met}}$ in the P site (P$_{\text{IN}}$ state) (reviewed in (2,3)).

The crystal structure of a 40S-eIF1 complex predicts a clash between eIF1 and Met-tRNA$_{\text{Met}}$ bound to the P site in
Figure 1. (A) Model describing conformational rearrangements of the PIC during scanning and start codon recognition. (i) eIF1 and the SE elements in the eIF1A CTT stabilize an open 40S conformation to which TC loads rapidly. (ii) The 43S PIC in the open conformation scans for an AUG codon with Met-tRNAi in the P_{OUT} state. The GAP domain in the N-terminal domain of eIF5 (5N) stimulates GTP hydrolysis to produce GDP・P_i, but P_i release is blocked. The unstructured NTT of eIF2B interacts with eIF1 to stabilize eIF1・40S association. (iii) On AUG recognition, Met-tRNAi moves from the P_{OUT} to P_{IN} state, clashing with eIF1. Movement of eIF1 disrupts its interaction with the eIF2B-NTT, which interacts with the eIF5-CTD instead. eIF1 dissociates from the 40S subunit, and the eIF1A SE elements interact with the eIF5-NTD to facilitate P_i release. (Below) Arrows summarize that eIF1 and eIF1A SE elements promote P_{OUT} and block transition to the P_{IN} state, whereas the scanning inhibitor (SI) element in the NTT of eIF1A stabilizes the P_{IN} state. (Adapted from (3,29)). (B) eIF5 Suic substitution G31R alters start codon regulation of GTP hydrolysis and P_i release from reconstituted 43S-mRNA PICs. The kinetics of GTP hydrolysis and P_i release from 43S PICs was measured after addition of WT eIF5 or G31R eIF5 and mRNAs (AUG or UUG). Aliquots from the reactions were quenched at different times with 100 mM EDTA. γ・32P-GTP and γ・32P-GDP were then separated using PEI-cellulose TLC and quantified by phosphorimager analysis. The fraction of GTP hydrolyzed versus time was plotted and the data fit with a double exponential rate equation. The fast phase corresponds to GTP hydrolysis and the slower phase to P_i release (10). The curves shown are WT eIF5 and AUG mRNA (red circles); WT eIF5 and UUG mRNA (blue circles); G31R eIF5 and AUG mRNA (red squares); or G31R eIF5 and UUG mRNA (blue squares). (C) Histograms showing the observed rate constants for GTP hydrolysis (k_1; left Y-axis) and P_i release (k_2; right Y-axis) from (B).
the classical P/P state (4). Moreover, a comparison of recent structures of mammalian 40S eIF1, 40S-eIF1-eIF1A and 40S-eIF1A-mRNA-tRNA complexes predicts a re-orientation of Met-tRNA\textsubscript{\textsc{\textit{A}}} from a position tilted toward the E-site (likened to P\textsubscript{\textsc{\textit{OUT}}} in complexes containing eIF1) to a state closer to the canonical P site location, dubbed P/1 and likened to P\textsubscript{\textsc{\textit{P}}}, in PICs lacking eIF1; and also that the P/1 location clashes with eIF1 (5). These findings support the notion that stable base-pairing of Met-tRNA\textsubscript{\textsc{\textit{A}}} with AUG in the P site will displace eIF1 and thereby trigger movement of the eIF5 NTD toward the eIF1A CTT, Pi release from eIF2-GDP-Pi, and rearrangement of the PIC to the closed, scanning-arrested conformation (3) (Figure 1A).

The GAP function of eIF5 is lodged in its N-terminal domain (NTD) (6), and requires Arg-15 in the unstructured N-terminal tail (NTT) (7) to accelerate GTP hydrolysis but not for binding eIF2 (8–10). There is evidence that Arg-15 acts as an ‘Arg finger’ that inserts into the eIF2y GTP binding pocket to stabilize the transition state for GTP hydrolysis (9); however, GAP function is also highly dependent on PIC assembly (8–10). Thus, whereas yeast eIF5 increases the rate of GTP hydrolysis by free TC by ∼10\textsuperscript{3}-fold, the stimulation is ∼10\textsuperscript{6}-fold in 43S PICs reconstituted with eIFs -1 and -1A, TC and eIF5 (10). It is not understood how the PIC contributes to eIF5 GAP function.

A previous study indicated that regulating the GAP activity of eIF5 has an important role in accurate selection of AUG start codons, based on analysis of the SUI5 mutation in eIF5, which substitutes Arg for Gly-31 (G31R) of AUG start codons, based on analysis of the activity of eIF5 has an important role in accurate selection and -1A, TC and eIF5 (10). It is not understood how the aberrant activities of the G31R mutant in regulating Pi, release and rearrangement to the closed PIC conformation in vitro. In this way, we obtained evidence that both aspects of eIF5 function are crucial to achieve both high efficiency and accuracy of initiation in vivo.

**MATERIALS AND METHODS**

**Plasmids construction**

Plasmids used in this study are listed in Table 1. YCpTIF5 (TIF5-FL, LEU2) (13) encoding eIF5 tagged with FLAG epitope at the C-terminus, was modified by replacing the unique Nde I site (CATATG) with (AAGATG), yielding plasmid pAS5-101. TIF5 mutant alleles were constructed by fusion polymerase chain reaction (PCR) using pAS5-101 as template. The fusion PCR products were inserted between the EcoR I and Sal I sites of YCplac111 (sc) or YEplac181 (hc), and the subcloned fragments of all mutant constructs were confirmed by DNA sequencing. TIF11 mutant alleles were constructed by fusion PCR using p3390, containing WT TIF11 as template, as described previously (14). The fusion PCR products were inserted between the EcoR I and Sal I sites of YCplac111 (sc) YEplac181 (hc) or YCplac22, and the subcloned fragments of all mutant constructs were confirmed by DNA sequencing. Plasmids for in vitro expression of eIF5 variants were generated by mutagenesis of pTYB2 eIF5 using the Quik Change II site-directed mutagenesis kit (Agilent Technologies).

**Yeast strain construction**

Yeast strains used in this study are listed in Table 2. The tif5Δ his4-301 strain ASY100 was constructed as follows. A 1.92 kbp DNA fragment containing a portion of the tif5Δ::kanMX4 allele was amplified by PCR from genomic DNA of a yeast heterozygous tif5Δ::kanMX4/TIF5 diploid strain obtained from Open Biosystems (#YSC1021-672509) using primers F6 (5′-CATCGCGAAGTATGAACGAAAAAAA-3′) and F7 (5′-TACGCATGCAGATCGGAGCCTAAT-3′). The PCR product was used to transform a derivative of strain H2994 carrying plasmid p3342 (TIF5, UR3) to G418-resistance, replacing chromosomal TIF5 with tif5Δ::kanMX4, generating strain ASY100. The gene replacement was verified by PCR analysis of chromosomal DNA using the appropriate primers. ASY137 was derived from ASY100 by replacing p3342 with TIF5+ TRP1 plasmid pAS5-134 by counter-selection on 5-FOA medium. Strain PMY17, in which TIF5 is under control of the GALI promoter, was generated from strain H3582 by the one-step PCR strategy using the kanMX4::PGAL1 cassette (15), selecting for resistance to kanamycin on rich
medium containing galactose as carbon source. Integration of the kanMX4::P\textsubscript{GAL1} cassette at the correct chromosomal location was verified by PCR analysis of genomic DNA using the appropriate primers.

### Biochemical assays with yeast extracts

Assays of β-galactosidase activity in whole cell extracts (WCEs) were performed as described previously (16). For western analysis, WCEs were prepared by trichloroacetic acid extraction as described previously (17), and immunoblot analysis was conducted as described (14) using antibodies against FLAG epitope to detect eIF5-FL proteins or against eIF2Be/Gcd6.

### Biochemical assays in the reconstituted yeast system

**Buffers and reagents.** The reconstitution (‘recon’) buffer was composed of 30 mM HEPES-KOH (pH 7.4), 100 mM KOAc (pH 7.4), 3 mM Mg(OAc)\(_2\) and 2 mM DTT. The enzyme storage buffer was composed of 20 mM HEPES-KOH (pH 7.4), 2 mM DTT and 10% glycerol. Purification of all components was performed as described previously (18). The model mRNAs used were of the sequence GGAA(UC)\(_7\)UNNN(CU)\(_{10}\)C, where NNN was either AUG or UUG, (referred to as mRNA(AUG) and mRNA(UUG), respectively).

**Purification of eIF5 mutants.** The eIF5 mutants were expressed in BL21(DE3) Codon Plus cells (Agilent Technologies). WT eIF5 and its mutants were then purified using the IMPACT system (New England Biolabs) as described previously (18).

**Fluorescent labeling of WT eIF1A.** WT eIF1A was labeled at its C-terminus with Cys-Lys-e-fluorescein dipeptide, using the expressed protein ligation system as previously described (19).

**GTP hydrolysis and P\(_1\) release kinetics.** The kinetics of GTP hydrolysis and phosphate release from 43S complexes in response to start codon recognition was measured using a rapid quench device (Kintek) as described previously (20). TC was formed at 4X concentration: 3.2 μM eIF2, 800 nM Met-tRNA\(_i\) and 250 pM GTP. All experiments were repeated 2–5 times.

GTP hydrolysis by isolated TC in presence of the eIF5 variant was measured as follows. TC was formed with 800 nM of eIF2, 800 nM Met-tRNA\(_i\), and 250 pM γ\(_{32}\)P-GTP in 1X recon buffer for 15 min at 26°C. Ribosomal complex was also made at 4× concentration in 1X recon buffer using 800 nM 40S subunits, 3.2 μM eIF1 and 3.2 μM eIF1A. Equal volumes of TC and ribosomal complex were mixed with 2 μM of eIF5 variant, and 20 μM mRNA (AUG or UUG) in a rapid quench. Reactions were quenched at different times with 100 mM ethylenediaminetetraacetic acid (EDTA). The samples were then run on PEI-Cellulose TLC plates using 0.4 M KPO\(_4\) buffer, pH 4.0 as the mobile phase, followed by PhosphorImager analysis to quantify the fraction of GTP hydrolyzed over time. The data were fit with a double exponential rate equation. The first phase corresponds to GTP hydrolysis and the second phase corresponds to P\(_1\) release, which drives GTP hydrolysis forward (10). All experiments were repeated 2–5 times.
rImager analysis to quantify the fraction of P\textsubscript{i} formed over time. The resulting data were fit with a straight line.

**RESULTS**

The *SUI5* mutation in eIF5 alters regulation of GTP hydrolysis and gated P\textsubscript{i} release

Because eIF5 is a GAP for eIF2 (8–10), we sought to determine the effect of the eIF5 *SUI5/G31R* mutation on GTP hydrolysis and subsequent P\textsubscript{i} release from eIF2 in the PIC. Our previous results indicated that P\textsubscript{i} release is strongly regulated by recognition of the start codon in the mRNA, whereas GTP hydrolysis itself can occur rapidly prior to start codon recognition (10). We assayed eIF5-stimulated GTP hydrolysis and P\textsubscript{i} release in reconstituted 43S-mRNA PICs containing 40S subunits, eIF1, eIF1A, TC assembled with [\textsuperscript{\gamma-32P}]GTP, eIF5 and a model mRNA containing an AUG or UUG start codon. The PICs were pre-assembled with eIF2, which drives the GTP hydrolysis reaction to completion, eIF1 dissociates from the PIC, triggering Pi release and the Pi from this reaction is observed following the denaturing quench. Upon AUG recognition, eIF1 dissociates from the PIC, triggering P\textsubscript{i} release from eIF2, which drives the GTP hydrolysis reaction to

---

**Table 2. Yeast strains used in this study**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Description</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>H2994</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)}</td>
<td>(31)</td>
</tr>
<tr>
<td>ASY100</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 p3342 [TIF5, URA3]</td>
<td>This study</td>
</tr>
<tr>
<td>ASY101</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-101</td>
<td>This study</td>
</tr>
<tr>
<td>ASY103</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-103</td>
<td>This study</td>
</tr>
<tr>
<td>ASY105</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-135</td>
<td>This study</td>
</tr>
<tr>
<td>ASY109</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-107</td>
<td>This study</td>
</tr>
<tr>
<td>ASY110</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-108</td>
<td>This study</td>
</tr>
<tr>
<td>ASY112</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-106</td>
<td>This study</td>
</tr>
<tr>
<td>ASY121</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-112</td>
<td>This study</td>
</tr>
<tr>
<td>ASY123</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-136</td>
<td>This study</td>
</tr>
<tr>
<td>ASY124</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-116</td>
<td>This study</td>
</tr>
<tr>
<td>ASY125</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-117</td>
<td>This study</td>
</tr>
<tr>
<td>ASY137</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif5\textsuperscript{Δ-}::kanMX4 pAS5-134</td>
<td>This study</td>
</tr>
<tr>
<td>PMY01</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} suil::hisG p1200 [SUI1, URA3]</td>
<td>(23)</td>
</tr>
<tr>
<td>ASY230</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} suil::hisG pJC39 [SUI1-93-97, TRP1] p\textsubscript{GAL1-}::TIF5::kanMX6</td>
<td>This study</td>
</tr>
<tr>
<td>ASY250</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} suil::hisG pPM21 [SUI1, TRP1] p\textsubscript{GAL1-}::TIF5::kanMX6</td>
<td>This study</td>
</tr>
<tr>
<td>H3882</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif1\textsuperscript{Δ} p3392 [TIF11, URA3]</td>
<td>(33)</td>
</tr>
<tr>
<td>PMY17</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif1\textsuperscript{Δ} p3392 [TIF11, URA3]</td>
<td>This study</td>
</tr>
<tr>
<td>ASY237</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif1\textsuperscript{Δ} pAS5-142 [TIF11, TRP1] p\textsubscript{GAL1-}::TIF5::kanMX6</td>
<td>This study</td>
</tr>
<tr>
<td>ASY238</td>
<td>*MAT\textsuperscript{ura3-52} trp1 \textsuperscript{Δ63} leu2-3, leu2-112 his4-301 (ACG)} tif1\textsuperscript{Δ} pAS5-130 [TIF11-FGESEDE\textsubscript{121-127}AAAAAA, TIF11-93-128FAAAA, TRP1] p\textsubscript{GAL1-}::TIF5::kanMX6</td>
<td>This study</td>
</tr>
</tbody>
</table>

**Kinetics of eIF1A dissociation.** Kinetic experiments measuring the dissociation of WT eIF1A from 43S complexes were carried out as described previously (12) in reactions with the following concentrations: 15 nM eIF1A-Fl, 1 \mu M eIF5 variant, 120 nM 40S, 10 \mu M mRNA (AUG or UUG), 300 nM eIF2, 150 nM Met-tRNA\textsubscript{i}, and 1 mM GDPNP Mg\textsuperscript{2+}. Buffer conditions were 30 mM HEPES (pH 7.4), 100 mM potassium acetate, 3 mM Mg(OAc)\textsubscript{2}, and 2 mM dithiothreitol. The fluorophore was excited at 497 nm and fluorescence anisotropy was monitored at 520 nm for up to 3 h, as necessary. Reactions containing fluorescence-labeled WT eIF1A were incubated for 30 min after the addition of TC. Dissociation of eIF1A-Fl was initiated by addition of 15 \mu M unlabeled eIF1A as a chase. The reaction was carried out on a Fluorolog-3 spectrophotometer (JobinYvon Horiba). Data were fit using single or double exponential rate equations, as appropriate. All kinetic experiments were repeated 3 times.
completion, producing a second, slower phase with a rate constant of ~0.6 s⁻¹ (10). This slower, second phase of the reaction corresponds to AUG-dependent Pi release from the PIC. Note that in this experimental set-up GTP hydrolysis and Pi release occur concurrently because eIF5 and mRNA are added together, and the reaction has biphasic kinetics with the rate constants for the fast and slow phases, $k_1$ and $k_2$, corresponding to GTP hydrolysis and Pi release, respectively. By contrast, when eIF5 is added in the absence of a model mRNA containing a start codon, Pi release is dramatically reduced (10).

In accordance with previous findings (10), rapid binding to PICs of a model mRNA with an AUG start codon (mRNA(AUG)) resulted in an observed rate constant for Pi release of ~0.70 s⁻¹, which was reduced by a factor of ~2 for complexes assembled with mRNA(UUG) instead (Figures 1B and C and Table 3, WT AUG versus UUG, $k_2$ values). The rate constant for GTP hydrolysis is also somewhat lower for UUG versus AUG complexes (Figures 1B-C & Table 3, WT AUG versus UUG, $k_1$ values). Relative to WT eIF5, the G31R mutant reduced the rate of Pi release in response to mRNA(AUG) by ~2-fold but increased it by a similar factor in response to mRNA(UUG) (Figures 1B-C and Table 3; WT versus G31R, $k_2$ values). The rate of GTP hydrolysis is also reduced to 1.5-fold and increased nearly 2-fold by the G31R mutation with mRNA(AUG) and mRNA(UUG), respectively (Figures 1B-C and Table 3, WT versus G31R, $k_1$ values). Thus, G31R provokes a switch in the differential between AUG and UUG in the rates of both GTP hydrolysis and Pi release relative to those seen with WT eIF5, which is consistent with the elevated UUG:AUG initiation ratio (Sui⁻ phenotype) of this mutant in vivo. Because Pi release is the rate-limiting step of conversion of eIF2 from its GTP- to GDP-bound states, the differential effects of G31R on the rate constants of Pi release ($k_2$) at UUG versus AUG likely has the greater impact on the fidelity of start codon selection in cells.

Genetic characterization of intragenic suppressors of the eIF5-G31R (SUI5) substitution

We reasoned that one way to establish the physiological relevance of the effect of eIF5-G31R on gated Pi release would be to identify intragenic suppressors of the Sui⁻ phenotype of the G31R mutation and determine if they also diminish the effect of G31R on Pi release in vitro. As described above, Sui⁻ mutations can be identified by their ability to restore growth of his4-301 cells on media lacking histidine by increasing initiation at the third, UUG codon in his4-301 mRNA, which lacks an AUG start codon (21). Introducing TIF5-G31R on a plasmid restores histidine prototrophy in his4-301 cells containing WT TIF5 in the chromosomes, indicating dominant His⁺/Sui⁻ phenotypes; however, TIF5-G31R cannot support cell viability as the only source of eIF5 (11). We sought to identify eIF5 intragenic suppressor mutations that would overcome the dominant Sui⁻ phenotype of TIF5-G31R (referred to below as just G31R). To this end, we combined G31R with each of three eIF5 mutations, M18V, T34N and G62S, originally identified by Donahue et al. by their ability to suppress the slow-growth (Slg⁻ phenotype of known Sui⁻ mutations in eIF1 (for G62S and M18V) or eIF2b (for T34N) (T. Donahue, unpublished observations). It was shown subsequently that G62S suppresses the His⁺ phenotype of the Sui⁻ SUI3-2 mutation in eIF2B, consistent with an Ssu⁻ (suppressor of Sui⁻) hyperaccuracy phenotype (22). The M18V substitution maps in the unstructured NTD of eIF5 only two residues from the key GAP residue Arg-15 (7), whereas T34N and G62S map in the globular portion of the eIF5 NTD. We also combined G31R with the eIF5 mutations, K33E and L61A, as it was proposed that K33 functions as the secondary, stabilizing basic residue described in other GAPs (7) and is adjacent to the residue altered by T34N; and L61 is a highly conserved residue adjacent to the residue altered by suppressor G62S. As described below, the eIF5 mutations we examined fell into three genetic categories: (i) suppression of the His⁺/Sui⁻ phenotype but not the lethality of G31R, in the case of M18V; (ii) suppression of both the His⁺/Sui⁻ phenotype and lethality of G31R, for G62S and K33E and (iii) suppression of lethality but not the His⁺/Sui⁻ phenotype of G31R, for L61A and T34N. These genetic results provided the first indication that distinct biochemical mechanisms underlie the Ssu⁻ phenotypes of different G31R suppressors.

Each of the mutations mentioned above was combined with G31R in a TIF5 allele that also contains the coding sequences for a C-terminal FLAG epitope. The resulting double-mutant alleles were introduced on LEU2 plasmids and transformed into a his4-301 tif5Δ ura3 strain harboring untagged TIF5⁺ on a URA3 plasmid. We first established that the expression level of all mutant proteins was comparable to FLAG-tagged WT eIF5 by western analysis using FLAG antibody of WCEs prepared from strains either before or after eviction of the TIF5⁺ URA3 plasmid (Supplementary Figure S1). We then evaluated suppression of the dominant His⁺/Sui⁻ phenotype of G31R by examining growth of the double mutants on −His medium containing only 0.1% of the histidine supplement normally provided in +His medium. Suppression of the lethality of G31R was scored by the ability of the strain to survive eviction of the TIF5⁺ URA3 plasmid by counter-selection on (+His) medium containing 5-fluoro-orotic acid (5-FOA).

M18V strongly suppresses the dominant His⁺/Sui⁻ phenotype, but not the recessive lethality, conferred by G31R. Thus, transformants harboring tif5-G31R M18V fail to grow on −His medium in the presence of TIF5⁺, indicating the Ssu⁻ phenotype, and also cannot grow on 5-FOA medium, indicating inviability of the cells following eviction of TIF5⁺ (Figure 2A, rows 3–4). The failure to grow on the −His medium does not result from a general growth defect, as the tif5-G31R M18V strain grows better on +His medium than does the parental His⁺ tif5-G31R strain, which displays the dominant Sgl⁻ phenotype conferred by G31R (Figure 2B, rows 3–4 versus row 2).

To confirm the Ssu⁻ phenotype of M18V in the G31R M18V strain, we assayed matched HIS4-lacZ fusions with AUG or UUG start codons in tif5Δ strains harboring TIF5-G31R or TIF5-G31R M18V on a LEU2 plasmid and also a TRP1 TIF5⁺ plasmid (provided to rescue growth of the G31R single mutant). As expected, the G31R strain displays an elevated UUG:AUG initiation ratio for these reporters, of ~0.28, well above that seen in the strain contain-
in (D) harboring the indicated plasmid-borne reporter plasmids. Transformants were cultured on SC-L supplemented with either 0.3 mM histidine (-LU) or 0.0003 mM histidine (-LUH), or to SC-L supplemented with 5.2 mM 5-FOA (5-FOA). Cells were incubated for 3d (-LU) or 6d (-LUH and 5-FOA) at 30° C. (B) 10-fold serial dilutions of strains described in (A) were spotted on SC-L and incubated for 3d at 30° C. (C) Derivatives of his4-301Δ strain ASY137 harboring a TIF5⁺ TRP1 plasmid and the indicated TIF5 alleles on LEU2 plasmids (hc WT on pAS5-132, sc WT on pAS5-101, G31R on pAS5-111, G31R,M18V on pAS5-115, G31R,K33E on pAS5-117, G31R,G62S on pAS5-112, G31R,L61A on pAS5-116 and hc G31R,T34N on pAS5-136) were replica-plated to SC-LU supplemented with either 0.3 mM histidine (-LU) or 0.0003 mM histidine (-LUH), or to SC-L supplemented with 5.2 mM 5-FOA (5-FOA). Cells were incubated for 3d (-LU) or 6d (-LUH and 5-FOA) at 30° C. (D) 10-fold serial dilutions of strains described in (A) were spotted on SC-L and incubated for 3d at 30° C. (C) Derivatives of his4-301Δ strain ASY137 harboring a TIF5⁺ TRP1 plasmid and the indicated TIF5 alleles on LEU2 plasmids were transformed with HIS4-lacZ reporter plasmids with AUG (p367) or UUG (p391) start codons. Cells were cultured in SC lacking leucine, tryptophan and uracil at 30° C and β-galactosidase activities were measured in whole cell extracts (WCEs). Ratios of β-galactosidase expressed from the UUG to AUG reporter were calculated from three independent transformants and mean ratios and and S.E.M.s (error bars) were plotted. (D) Sgl⁺ and His⁺/Sui⁺ phenotypes of the his4-301 tif5Δ strains harboring TIF5 alleles described in (A), and isogenic strains containing M18V on pAS5-106, K33E on pAS5-108, G62S on pAS5-103, L61A on pAS5-107 or hc T34N on pAS5-135, were determined by spotting serial 10-fold dilutions on SC-LU supplemented with 0.3 mM His (+His) or 0.0003 mM His (-His) and incubated for 3d (-His) or 6d (+His) at 30° C. (E) Derivatives of his4-301Δ strain ASY250 with the chromosomal TIF5 gene under the GAL1 promoter (pGAL1-TIF5) harboring SUII⁺ on a TRP1 plasmid and the indicated TIF5 alleles on LEU2 plasmids were transformed with the AUG or UUG HIS4-lacZ reporter plasmids. Transformants were cultured in synthetic minimal medium with 2% galactose as carbon source and supplemented with 0.3 mM histidine (5Gal+H) and then shifted to synthetic minimal medium with 2% glucose (SD+H) for 16 h. UUG:AUG initiation ratios for the HIS4-lacZ reporters were determined as in (C). (F) HIS4-lacZ UUG:AUG initiation ratios were measured as in (C) for strains described in (D) harboring the indicated plasmid-borne TIF5 alleles. For panels A and D, images have been cropped from results obtained from different plates examined in parallel in the same experiments.

Figure 2. Genetic characterization of intragenic suppressors of TIF5 allele SU55/G31R. (A) Derivatives of his4-301 tif5Δ strain ASY100 harboring a TIF5⁺ URA3 plasmid and the indicated TIF5-FL alleles on LEU2 plasmids (hc WT on pAS5-132, sc WT on pAS5-101, G31R on pAS5-111, G31R,M18V on pAS5-115, G31R,K33E on pAS5-117, G31R,G62S on pAS5-112, G31R,L61A on pAS5-116 and hc G31R,T34N on pAS5-136) were replica-plated to SC-LU supplemented with either 0.3 mM histidine (-LU) or 0.0003 mM histidine (-LUH), or to SC-L supplemented with 5.2 mM 5-FOA (5-FOA). Cells were incubated for 3d (-LU) or 6d (-LUH and 5-FOA) at 30° C. (B) 10-fold serial dilutions of strains described in (A) were spotted on SC-L and incubated for 3d at 30° C. (C) Derivatives of his4-301Δ strain ASY137 harboring a TIF5⁺ TRP1 plasmid and the indicated TIF5 alleles on LEU2 plasmids were transformed with HIS4-lacZ reporter plasmids with AUG (p367) or UUG (p391) start codons. Cells were cultured in SC lacking leucine, tryptophan and uracil at 30° C and β-galactosidase activities were measured in whole cell extracts (WCEs). Ratios of β-galactosidase expressed from the UUG to AUG reporter were calculated from three independent transformants and mean ratios and and S.E.M.s (error bars) were plotted. (D) Sgl⁺ and His⁺/Sui⁺ phenotypes of the his4-301 tif5Δ strains harboring TIF5 alleles described in (A), and isogenic strains containing M18V on pAS5-106, K33E on pAS5-108, G62S on pAS5-103, L61A on pAS5-107 or hc T34N on pAS5-135, were determined by spotting serial 10-fold dilutions on SC-LU supplemented with 0.3 mM His (+His) or 0.0003 mM His (-His) and incubated for 3d (-His) or 6d (+His) at 30° C. (E) Derivatives of his4-301Δ strain ASY250 with the chromosomal TIF5 gene under the GAL1 promoter (pGAL1-TIF5) harboring SUII⁺ on a TRP1 plasmid and the indicated TIF5 alleles on LEU2 plasmids were transformed with the AUG or UUG HIS4-lacZ reporter plasmids. Transformants were cultured in synthetic minimal medium with 2% galactose as carbon source and supplemented with 0.3 mM histidine (5Gal+H) and then shifted to synthetic minimal medium with 2% glucose (SD+H) for 16 h. UUG:AUG initiation ratios for the HIS4-lacZ reporters were determined as in (C). (F) HIS4-lacZ UUG:AUG initiation ratios were measured as in (C) for strains described in (D) harboring the indicated plasmid-borne TIF5 alleles. For panels A and D, images have been cropped from results obtained from different plates examined in parallel in the same experiments.
ing only TIF5+ (~0.05). Importantly, the UUG:AUG ratio drops to ~0.11 in the G31R,M18V strain (Figure 2C, columns 1–3), indicating that M18V reduces the hypoa-ccuracy phenotype in the manner expected of an Ssu− mutation, even though it does not overcome the lethality of G31R.

In contrast to the G31R,M18V mutant, the two mutants in which G31R is combined with G62S or K33E can grow on 5-FOA medium (Figure 2A, rows 5 and 6), indicating suppression of the recessive lethality of G31R. As might be expected, G62S and K33E also suppress the dominant Sgl− phenotype of G31R on +His medium (Figure 2B, rows 5 and 6 versus row 3). Both double mutants also fail to grow on −His medium (Figure 2A, rows 5 and 6) and, consistent with this, display reduced UUG:AUG initiation ratios compared to the G31R single mutant (Figure 2C, columns 2 versus 4–5). Thus, K33E and G62S suppress the Sui− phenotype of G31R, exhibiting Ssu− phenotypes, in addition to overcoming the lethality of G31R.

T34N and L61A comprise the third class of eIF5 mutants we identified, which suppress the recessive lethality but not the dominant His+/Sui+ phenotype of G31R, as the double or triple mutants grow on both 5-FOA and −His medium (Figure 2A, rows 7 and 8 versus 3). Consistent with their His+ phenotypes, when examined in cells harboring TIF5+, these double mutants display no reduction in the UUG:AUG initiation ratio (Figure 2C, columns 6–7 versus 2), indicating that L61A and T34N are Ssu+ rather than Ssu− eIF5 substitutions.

With the exception of the lethal G31R and G31R,M18V alleles, we also characterized the phenotypes of the mutant TIF5 alleles after evicting TIF5+ by 5-FOA selection. These strains showed much the same behavior on −His medium observed prior to TIF5+ eviction described above. Thus, the double mutations combining G31R with T34N or L61A allow growth on −His medium (Figure 2D, rows 1 versus 8 and 10, −His data) indicating a failure to suppress the Sui− phenotype of G31R, even though they have slow-growth (Sgl−) phenotypes on +His medium (Figure 2D, rows 1 versus 8 and 10, +His data) that should limit their ability to grow on the −His medium. The Sgl− phenotypes of the G31R,T34N and G31R,L61A double mutants are more severe than observed in the corresponding strains harboring the suppressor mutations on their own without G31R (Figure 2D, cf. 7–8 and 9–10, +His), indicating that T34N and L61A do not overcome the growth defects conferred by G31R even though they suppress its lethality.

Following eviction of TIF5+, the two viable double mutants in which G31R is combined with G62S or K33E show little or no growth on −His medium (Figure 2D, rows 4 and 6, −His), consistent with the Ssu− phenotypes observed in the strains harboring TIF5+ (Figure 2A). To confirm this conclusion, we measured the UUG:AUG initiation ratios conferred by the TIF5 suppressor alleles in a strain containing chromosomal TIF5 under the GAL1 promoter (Pgal·TIF5), which expresses WT eIF5 only on galactose medium. The HIS4-lacZ reporters were assayed after incubating cells for 16 h in glucose medium, which is sufficient to deplete the WT eIF5 encoded by Pgal·TIF5 by ~75% (23). This approach allowed us to compare the UUG:AUG initiation ratios conferred by the G31R and G31R,M18V mutations, which are lethal in the absence of WT eIF5. As shown in Figure 2E, the G31R single mutation confers a UUG:AUG ratio of ~0.45, considerably larger than it produces in a strain also containing TIF5+ (0.28, Figure 2C), indicating that the Sui− phenotype of G31R is dampened by WT eIF5. As shown above, the M18V substitution greatly reduces, but does not abolish, the elevated UUG:AUG ratio produced by G31R in the G31R,M18V double mutant, which remains ~2-fold higher than the ratio measured in WT cells (Figure 2E, columns 1, 3–4). The G62S and K33E also strongly suppress the Sui− phenotype of G31R, reducing the UUG:AUG ratio in the relevant double mutants to essentially the WT level (Figure 2E, cf. columns 1 and

<table>
<thead>
<tr>
<th>eIF5 variant</th>
<th>AUG</th>
<th></th>
<th>UUG</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><em>k</em></td>
<td></td>
<td><em>k</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>obs</td>
<td>Amplitude</td>
<td>obs</td>
<td>Amplitude</td>
</tr>
<tr>
<td>1. WT</td>
<td>25 ± 3.0</td>
<td>0.55 ± 0.02</td>
<td>18 ± 2.0</td>
<td>0.60 ± 0.03</td>
</tr>
<tr>
<td></td>
<td>0.65 ± 0.07</td>
<td>0.45 ± 0.02</td>
<td>0.38 ± 0.05</td>
<td>0.40 ± 0.03</td>
</tr>
<tr>
<td>2. G31R</td>
<td>16 ± 4.0</td>
<td>0.40 ± 0.04</td>
<td>32 ± 4.0</td>
<td>0.50 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.32 ± 0.04</td>
<td>0.60 ± 0.04</td>
<td>0.70 ± 0.06</td>
<td>0.50 ± 0.02</td>
</tr>
<tr>
<td>3. M18V</td>
<td>0.4 ± 0.10</td>
<td>0.4 ± 0.05</td>
<td>0.6 ± 0.2</td>
<td>0.3 ± 0.01</td>
</tr>
<tr>
<td></td>
<td>0.06 ± 0.01</td>
<td>0.6 ± 0.05</td>
<td>0.08 ± 0.02</td>
<td>0.7 ± 0.01</td>
</tr>
<tr>
<td>4. G31R,M18V</td>
<td>0.1 ± 0.02</td>
<td>0.4 ± 0.01</td>
<td>0.13 ± 0.02</td>
<td>0.4 ± 0.01</td>
</tr>
<tr>
<td></td>
<td>0.028 ± 0.001</td>
<td>0.6 ± 0.01</td>
<td>0.03 ± 0.01</td>
<td>0.6 ± 0.01</td>
</tr>
<tr>
<td>5. G62S</td>
<td>28 ± 2.0</td>
<td>0.50 ± 0.03</td>
<td>22 ± 2.0</td>
<td>0.50 ± 0.01</td>
</tr>
<tr>
<td></td>
<td>0.60 ± 0.08</td>
<td>0.50 ± 0.03</td>
<td>0.40 ± 0.04</td>
<td>0.50 ± 0.01</td>
</tr>
<tr>
<td>6. G31R,G62S</td>
<td>32 ± 4.0</td>
<td>0.35 ± 0.05</td>
<td>24 ± 2.0</td>
<td>0.30 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>0.60 ± 0.05</td>
<td>0.65 ± 0.05</td>
<td>0.3 ± 0.02</td>
<td>0.70 ± 0.02</td>
</tr>
</tbody>
</table>

*All errors are SE calculated by SD/√n; n = number of experiments.*
5–6). By contrast, L61A does not reduce the UUG:AUG ratio at all in the G31R,L61A double mutant (Figure 2E, column 7 versus 3), in agreement with the results above in cells co-expressing WT eIF5 at native levels (Figure 2C, column 7 versus 2). However, T34N produces a reduction in the UUG:AUG ratio only slightly less than that observed for M18V in the relevant double mutants harboring G31R (Figure 2E, columns 3, 4 and 8). This last result differs from that observed in cells expressing WT eIF5, in which T34N conferred no reduction in UUG:AUG ratio in the G31R,T34N double mutant (Figure 2C, columns 2 and 7). This discrepancy seems to indicate that the ability of T34N to overcome the hypoaccuracy phenotype of G31R in the G31R,T34N double mutant is masked by the presence of WT eIF5.

Because all of the suppressors except L61A conferred a Slg− phenotype when examined as single eIF5 substitutions in the absence of G31R (Figure 2D, rows 2, 3, 5 and 9), we wondered if they might affect AUG selection on their own. In fact, M18V, L61A, G62S and T34N all confer significant increases in the UUG:AUG initiation ratio (Figure 2F). The fact that these strains do not display a His+ phenotype (Figure 2D, rows 2, 5, 7 and 9, −His) probably reflects a combination of their Slg− phenotypes (evident on +His medium) and the relatively moderate increases in UUG initiation they confer (Figure 2F), but it might also involve a defect in another function required for growth under conditions of histidine limitation. Indeed, we found that M18V and T34N diminish the translational induction of the GCN4 gene (data not shown), whose product mediates increased transcription of HIS4 and contributes to the His+ phenotype of many Sui− mutants. In any event, it is interesting that the M18V and G62S substitutions confer moderate Sui− phenotypes on their own (Figure 2F) even though they diminish the Sui− phenotype of the G31R mutant in the corresponding eIF5 double mutants (Figure 2C and E). This finding supports the idea that the effects of M18V and G62S on eIF5 function are influenced by the presence of the G31R substitution in the same polypeptide.

**Distinct effects of G31R suppressors M18V and G62S on the kinetics of GTP hydrolysis and P1 release**

The results above indicate that the M18V substitution in eIF5 confers nearly complete suppression of the Sui− phenotype of G31R, without overcoming the lethality of G31R in cells lacking WT eIF5. Given its location only three residues from a key catalytic residue (Arg-15) in the unstructured NTT, we hypothesized that M18V impairs GAP function in the G31R,M18V double mutant. To test this possibility, we assayed eIF5 stimulation of GTP hydrolysis and P1 release from eIF2 in reconstituted PICs. As described above in Figures 1B and C, the G31R single substitution reduces the rates of GTP hydrolysis and P1 release at AUG while increasing them at UUG, reversing the differential effects of AUG and UUG from those seen with WT eIF5 (Figures 3A and B WT versus G31R and Table 3, rows 1–2). In the G31R,M18V double mutant, M18V reduces the rates of P1 release at both AUG and UUG compared to those seen in the G31R single mutant (Figures 3A and B G31R,M18V versus G31R, k2 values), yielding rate constants at AUG and UUG that are 10- and 20-fold, respectively, below those observed with G31R eIF5 (Table 3, row 4 versus 2; k2 values). M18V in the double mutant also dramatically reduces the rates of GTP hydrolysis at AUG and UUG compared to those seen in the G31R single mutant, by factors of >150-fold (Figures 3A and B G31R,M18V versus G31R and Table 3, row 4 versus 2, k1 values), indicating a major defect in the GAP function of the double mutant. These strong defects in both GTP hydrolysis and P1 release at AUG likely account for the inability of M18V to suppress the lethality of G31R in vivo (Figure 2A). Combining M18V with G31R decreases the P1 release rates ~2-fold more at UUG than at AUG (Figures 3A and B G31R,M18V versus G31R, Table 3, row 4 versus 2, k2 values) to produce a UUG:AUG ratio of P1 release—the rate-limiting step—close to 1 in the double mutant. Although this ratio of release rates is still above that observed with WT eIF5, the trend is consistent with suppression of the Sui− phenotype of G31R by the M18V substitution.

The M18V substitution on its own results in 60- and 30-fold reductions in the rate constants for GTP hydrolysis with mRNA(AUG) and mRNA(UUG), respectively (Figures 3E and F WT versus M18V; Table 3, row 3 versus 1, k1 values), consistent with the proposed defect in GAP function. The rate constants for P1 release are also reduced, by 10- and 5-fold at AUG and UUG, respectively, compared to the corresponding rates of P1 release observed for WT eIF5, which leads to nearly identical reaction rates at UUG and AUG for the M18V variant (Table 3, row 3 versus 1, k2 values). Although these differences are small, this last observation is consistent with the moderate increase in UUG:AUG initiation ratio (weak Sui− phenotype) observed for the tif5-1M18V single mutant in vivo (Figure 2F).

To explore further the effect of the M18V substitution on the GAP activity of eIF5, we measured the slow rate of eIF5-dependent GTP hydrolysis by isolated eIF2-Met-tRNAi·GTP ternary complexes (10) using WT and M18V forms of eIF5. In this assay, pre-formed TCs are mixed with eIF5 to initiate GTP hydrolysis. Aliquots are removed at various times, mixed with a denaturing quench and the amount of P1, formed analyzed by thin-layer chromatography. Even in this context, in which GTP hydrolysis is not influenced by conformational changes in the PIC, the M18V substitution reduces the observed rate of GTP hydrolysis by >20-fold relative to the WT factor (Supplementary Figure S2; 0.0028 versus 0.0003 min−1 with WT and M18V, respectively), supporting the conclusion that M18V diminishes the GAP function of the factor.

The genetic analyses described above in Figure 2 indicated that the G62S substitution is also very effective in suppressing the Sui− phenotype of G31R in vivo. G62S on its own has no significant effect on the GTPase or P1 release rates at AUG versus UUG (Table 3, row 5 versus 1,) or on the rate of GTP hydrolysis by the isolated TC (Supplementary Figure S2). Importantly, however, when combined with G31R, the G62S suppressor essentially reverses the effects of G31R of elevating the rate of P1 release at UUG while depressing it at AUG, to reinitiate a nearly WT differential in rates between AUG and UUG (Figures 3C and D G31R,G62S versus G31R and Table 3, row 6 versus 2, k2 values). G62S also restores a WT rate of GTP hydrolysis at
Figure 3. Effects of eIF5 Sui− substitution G31R and its intragenic suppressors M18V and G62S on GTP hydrolysis and Pi release from reconstituted 43S-mRNA PICs. Double mutant derivatives of Sui− G31R eIF5 (G31R,M18V and G31R,G62S) were generated by combining M18V or G62S with G31R in the same recombinant eIF5 variants. The kinetics of Pi formation from the 43S PIC with a model mRNA with an AUG or UUG start codon were measured for these mutants as described in Figure 1B. With WT eIF5, the fast phase of the reaction was shown previously to correspond to GTP hydrolysis and the slow phase to Pi release, which drives GTP hydrolysis to completion (10). (A) GTP hydrolysis and Pi release with WT (circles), G31R (squares) and G31R,M18V (triangles) variants of eIF5 with AUG (red) or UUG (blue) mRNAs. GTP hydrolysis and Pi release was monitored for 4 min in case of G31R,M18V (shown in inset). (B) Observed rate constants for GTP hydrolysis ($k_1$; red and blue striped bars; left Y-axis) and Pi release ($k_2$; red and blue solid bars; right Y-axis) for the cases shown in (A). (C) GTP hydrolysis and Pi release with WT (circles), G31R (squares) and G31R,G62S (diamonds) eIF5 variants with AUG (red) or UUG (blue) mRNAs. (D) Observed rate constants for GTP hydrolysis ($k_1$) and Pi release ($k_2$) for the cases shown in (C). (E) GTP hydrolysis and Pi release with WT (circles) or M18V (inverted triangles) eIF5 variants with AUG (red) or UUG (blue) mRNAs. GTP hydrolysis and Pi release was monitored for 4 min in case of M18V (shown in inset). (F) Observed rate constants for GTP hydrolysis ($k_1$) and Pi release ($k_2$) for the curves shown in (E). Data in (B), (D) and (F) are the averages of three experiments and error bars represent standard errors of the mean.
AUG codons (Figures 3C and D G31R,G62S versus G31R and Table 3, row 6 versus 2, AUG, $k_1$ values). Note that unlike M18V, which was shown above to slow GTP hydrolysis and $P_i$ release on both AUG and UUG codons in the G31R,M18V double mutant, combining G62S with G31R actually increases the rates of these steps at AUG codons compared to those seen in the G31R single mutant (Figures 3C and D G31R,G62S versus G31R and Table 3 row 6 versus 2, AUG, $k_1$ and $k_2$), consistent with the viability of the G31R,G62S double mutant as the sole version of eIF5 in the cell (Figure 2A).

Although we sought to examine the effects of the eIF5-T34N suppressor on GTP hydrolysis and $P_i$ release, repeated attempts to express and purify both this variant and the eIF5-L61A mutant proteins were unsuccessful.

Distinct effects of G31R suppressors on stabilities of open and closed conformations of the PIC

In addition to affecting the regulation of $P_i$ release, we showed previously that the eIF5-G31R substitution also affects rearrangement of the PIC from the open, scanning conformation to the closed, scanning-arrested state (12). The rate of eIF1A dissociation from the PIC is a sensitive probe of this transition because eIF1A and eIF5 functionally interact on AUG recognition in a way that strengthens eIF1A binding to the PIC. This is manifested as an increase in amplitude or decrease in rate constant (or both) of the slower phase of the biphasic dissociation of eIF1A from the 43S-mRNA complex. The two kinetic phases of eIF1A dissociation are thought to represent the partitioning of PICs between open and closed conformations, with the fast and slow phases corresponding to the fractions of complexes in the open and closed states, respectively. It was demonstrated that eIF5-G31R reverses the differential effects of AUG versus UUG on eIF1A dissociation kinetics, indicating a shift in the balance between the two states of the PIC in favor of the closed complex at UUG codons and against it at AUG codons (12). We considered the possibility that, in addition to influencing P$_i$ release, the G62S and M18V substitutions might reverse the effect of G31R and preferentially destabilize the closed complex at UUG codons, thus contributing to their Suí⁻ phenotype. Accordingly, we examined how M18V and G62S influence the effects of G31R on eIF1A dissociation kinetics.

43S-mRNA(AUG) or 43S-mRNA(UUG) complexes were assembled with eIF1A (labeled at its C-terminus with fluorescein) in the presence of eIF5, chased with excess unlabeled eIF1A, and eIF1A dissociation was measured over time as the decrease in fluorescence anisotropy. Dissociation of WT eIF1A from the PIC is biphasic, with rate constants for the fast and slow phases designated $k_1$ and $k_2$, respectively. We defined an apparent equilibrium constant, $K_{amp}$, as the ratio of amplitudes of the slow to fast phases ($\alpha_2/\alpha_1$). Accordingly, $K_{amp}$ values >1 indicate that the slow phase dominates the reaction. In accordance with previous findings (12), WT eIF1A dissociates more slowly from AUG versus UUG complexes (Figure 4A), as dissociation from the AUG complexes is dominated by the slow phase ($K_{amp}$ of 6.0; Table 4, row 1), while replacing AUG with UUG reduces $K_{amp}$ to 4.0 and also increases $k_2$ by ~3-fold (row 2). These findings suggest that only approximately one-seventh of the PICs are in the open conformation at AUG ($K_{amp}$ of 6.0) whereas approximately one-fifth occupy the open conformation at UUG ($K_{amp}$ of 4.0), and the ~3-fold higher value of $k_2$ at UUG indicates that eIF1A is bound less stably in the closed conformation at UUG versus AUG. This latter finding could reflect a decreased strength of interaction between eIF1A and eIF5, which we have shown is a key event in mediating a proper response to start codon recognition (3,12).

As observed previously (12,24), the G31R eIF5 substitution essentially reverses the differential effects of AUG and UUG on eIF1A dissociation kinetics (Figure 4A). Relative to WT eIF5, the G31R mutant displays increased occupancy of the closed state at UUG ($K_{amp}$ increased ~2.5-fold; Table 4, row 4 versus 2) but decreased occupancy of the closed conformation at AUG ($K_{amp}$ decreased 2-fold; Table 4, row 3 versus 1), increasing the $K_{amp}$(UUG):$K_{amp}$(AUG) ratio from ~0.7 (WT) to ~3.3 (G31R). G31R also stabilizes eIF1A bound in the closed conformation at UUG ($k_2$ decreased by ~2-fold) while destabilizing it at AUG ($k_2$ increased by ~12-fold) (Table 4, rows 3–4 versus 1–2). Thus, G31R strongly favors the rearrangement to the closed conformation at UUG and disfavors this transition at AUG, consistent with its Suí⁻ phenotype.

Combining M18V with G31R in the G31R,M18V double mutant does not substantially alter the eIF1A dissociation kinetics (Figure 4B). The $K_{amp}$(UUG):$K_{amp}$(AUG) ratio (4.5) is relatively unchanged from that observed for the G31R single mutant (3.3) (Table 4, rows 7–8 versus 3–4), indicating that M18V does not reverse the dual effects of G31R of promoting the closed complex at UUG and disfavoring the open complex at AUG. Combining M18V with G31R does appear to destabilize eIF1A binding to the open conformation at UUG ($k_1$ increased by ~2.0-fold relative to the G31R mutant) and to stabilize its binding to the closed state at AUG ($k_2$ decreased by 2.5-fold relative to G31R) (Table 4, rows 7–8 versus 3–4). These latter effects might contribute to the ability of M18V to lower the UUG:AUG initiation ratio (Suí⁻ phenotype) in the G31R,M18V double mutant versus the G31R single mutant. On its own in otherwise WT eIF5, with an AUG start codon, M18V decreases the occupancy of the closed complex ($K_{amp}$ decreased by ~2-fold) (Table 4, rows 5–6 versus 1–2), which might contribute to the increased UUG:AUG initiation ratio (Suí⁻ phenotype) observed in vivo for the M18V single mutant (Figure 2F), although there is a similar effect on $K_{amp}$ at UUG codons.

Comparing the eIF1A dissociation kinetics between the G31R single mutant and the G31R,G62S double mutant indicates that the G62S suppressor exerts a significant effect on the ability of G31R to influence the open-to-closed transition at AUG versus UUG codons (Figure 4C). As noted above, G31R essentially reverses the partitioning of PICs between the open and closed conformations from that observed with WT eIF5 to favor the closed conformation at UUG and disfavor the closed state at AUG. The G62S substitution decreases the occupancy of the closed complex at UUG in the G31R,G62S double mutant relative to its value in the G31R single mutant ($K_{amp}$ decreased by ~4-fold), although it has a similar effect of disfavoring the closed state.
Figure 4. Effects of eIF5 intragenic suppressors M18V and G62S on the kinetics of eIF1A dissociation from reconstituted 43S mRNA PICs. Dissociation of fluorescein-labeled eIF1A from 43S mRNA complexes assembled with WT or mutant eIF5 was monitored by following the change in fluorescence anisotropy over time after the addition of a large excess of unlabeled WT eIF1A. The data were fit with a double exponential decay equation. Previous data indicate that the fast phase corresponds to dissociation of eIF1A from the ‘open’ conformation of the PIC and the second phase corresponds to dissociation from the ‘closed’ state. In order to highlight differences in the fast phases, the early time points of the respective eIF1A dissociation curves are shown in insets. The ratio of the amplitudes of the second phase (closed state) to first phase (open state) is defined as $K_{\text{amp}}$. (A) eIF1A dissociation from PICs assembled with WT (circles) and G31R (squares) eIF5 with mRNA(AUG) (red; $K_{\text{amp}}$ for WT is $6.0 \pm 0.7$ and for G31R is $3.0 \pm 0.2$) and mRNA(UUG) (blue; $K_{\text{amp}}$ for WT is $4.0 \pm 0.2$ and for G31R is $10 \pm 0.6$). (B) eIF1A dissociation from PICs assembled with G31R (squares) and G31R,M18V (triangles) eIF5 with mRNA(AUG) (red; $K_{\text{amp}}$ is $2.0 \pm 0.1$ for G31R,M18V) and mRNA(UUG) (blue; $K_{\text{amp}}$ is $9.0 \pm 1.0$ for G31R,M18V) mRNA. (C) eIF1A dissociation from PICs assembled with G31R (squares) and G31R,G62S (diamonds) eIF5 with mRNA(AUG) (red; $K_{\text{amp}}$ is $1.1 \pm 0.04$ for G31R,G62S) and mRNA(UUG) (blue; $K_{\text{amp}}$ is $2.3 \pm 0.3$ for G31R,G62S). (D) eIF1A dissociation from PICs assembled with WT (circles) and G62S (diamonds) eIF5 with mRNA(AUG) (red; $K_{\text{amp}}$ is $3.0 \pm 0.05$ for G62S) and mRNA(UUG) (blue; $K_{\text{amp}}$ is $2.3 \pm 0.06$ for G62S). All experiments were performed at least three times and errors are standard errors of the mean.
Intergenic suppression of Sui mutants of eIF2β, eIF1A and eIF1 by eIF5 suppressors

We sought next to obtain genetic evidence that the Ssu− phenotypes of the M18V and G62S eIF5 substitutions involve distinct molecular mechanisms in vivo. To this end, we asked whether M18V and G62S differ significantly in their ability to suppress Sui− substitutions in other initiation factors, beginning with the dominant Sui− mutation SUI3−2, encoding the S264Y substitution in eIF2β. Plasmid-borne SUI3−2 was introduced into SUI3+ tif5Δ strains also containing TIF5 alleles harboring single suppressor mutations (i.e. without G31R). As expected, in the TIF5+ his4−303 strain, SUI3−2 confers growth on −His medium (Figure 5A, rows 1–2) and elevates the UUG:AUG ratio above ~3 (Figure 5B, columns 1–2). The His+/Sui− phenotype of SUI3−2 is suppressed efficiently by the TIF5−M18V and TIF5−K33E alleles (Figure 5A, rows 2–4), with commensurate strong reductions in the UUG:AUG initiation ratio (Figure 5B, columns 2–4). Thus, these two eIF5 mutants are effective suppressors of the Sui− phenotypes of both SUI3−2 and (as shown above) the G31R allele of TIF5. Similarly, the L61A mutation, an ineffective suppressor of G31R/SUI3 (Figure 2) likewise only partially suppresses the His+ phenotype of SUI3−2 (Figure 5A, row 6 versus 2) and is relatively ineffective in reducing the elevated UUG:AUG ratio conferred by SUI3−2 (Figure 5B, columns 6 versus 2). It is interesting however that G62S, one of the strongest suppressors of G31R (Figure 2C and E), is a relatively inefficient suppressor of SUI3−2, failing to eliminate the His+ phenotype (Figure 5A, row 5) and reducing the UUG:AUG ratio by less than a factor of 2 (Figure 5B, column 6 versus 2). This last finding suggests that the Sui− phenotypes of tif5−G31R and SUI3−2 involve at least partially distinct mechanisms and that the G62S substitution in eIF5 more effectively compensates for the defect(s) conferred by tif5−G31R versus SUI3−2.

We also examined whether the eIF5 suppressors can mitigate the Sui− phenotype produced by the eIF1A mutation tif11−SE1*,SE2*,+F131, containing Ala substitutions in all but one (Phe-131) of the 20 residues that comprise scanning enhancer elements SE1 and SE2 in the eIF1A CTT (25). To this end, we introduced the TIF5 alleles into a his4−303 tif11Δ strain harboring chromosomal Pgal−TIF5 de-

at AUG (Kamp decreased by ~3-fold) (Table 4, rows 11–12 versus 3–4). Perhaps of greater significance, G62S also strongly destabilizes binding of eIF1A in the closed complex at UUG, increasing k2 by an order of magnitude in the G31R,G62S double mutant versus the G31R single mutant, while actually decreasing somewhat the k2 at AUG under the same circumstances (Table 4, rows 11–12 versus 3–4). Thus, in the presence of G31R, the G62S suppressor has a much larger destabilizing effect on interactions in the closed state at UUG than at AUG. These findings, together with the fact that G62S also mitigates the effects of G31R in promoting P1 release at UUG versus AUG codons (Figure 3C and D), can account for the ability of G62S to efficiently suppress the elevated UUG:AUG ratio conferred by G31R in vivo.

On its own in otherwise WT eIF5, G62S decreases the abundance of the closed complex at AUG (Kamp decreased by ~2-fold and also strongly stabilizes eIF1A binding in the closed state at AUG (k2 increased by ~10-fold) while producing a smaller reduction in the stability of the open complex at AUG (k1 increased by ~2.5-fold; Table 4, rows 9 versus row 1). It has a similar effect on partitioning between the open and closed states at UUG but destabilizes eIF1A binding in both states to similar extents (k1 and k2 increased by ~2.5- and ~2-fold, respectively; Table 4, row 10 versus row 2). The specific destabilization of interactions in the closed state at AUG codons would be expected to elevate the UUG:AUG initiation ratio (Figure 2F) because a preferential reduction in initiation at AUG codons would free up PICs to initiate at UUG codons, increasing UUG initiation by mass action (20).

### Table 4. Rate constants for eIF1A dissociation from 43S mRNA complexes

<table>
<thead>
<tr>
<th>eIF5 variants</th>
<th>mRNA</th>
<th>(k_1) (x 10^{-3} s^{-1})</th>
<th>(k_2) (x 10^{-3} s^{-1})</th>
<th>(\alpha_1)</th>
<th>(\alpha_2)</th>
<th>(K_{amp}(\alpha_2/\alpha_1))</th>
<th>(K_{amp}/K_{amp(AUG)})</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. WT</td>
<td>AUG</td>
<td>7.0 ± 1.0</td>
<td>0.4 ± 0.01</td>
<td>0.14 ± 0.01</td>
<td>0.86 ± 0.04</td>
<td>6.0 ± 0.7</td>
<td>3.0 ± 0.7</td>
</tr>
<tr>
<td></td>
<td>UUG</td>
<td>11 ± 3.0</td>
<td>1.1 ± 0.02</td>
<td>0.20 ± 0.01</td>
<td>0.80 ± 0.01</td>
<td>4.0 ± 0.2</td>
<td>1.3 ± 0.2</td>
</tr>
<tr>
<td>6. G31R</td>
<td>AUG</td>
<td>16 ± 3.0</td>
<td>5.0 ± 0.3</td>
<td>0.25 ± 0.02</td>
<td>0.80 ± 0.06</td>
<td>3.0 ± 0.2</td>
<td>0.1 ± 0.3</td>
</tr>
<tr>
<td>6. G31R</td>
<td>UUG</td>
<td>8.0 ± 2.0</td>
<td>0.5 ± 0.06</td>
<td>0.09 ± 0.01</td>
<td>0.91 ± 0.06</td>
<td>10 ± 0.6</td>
<td>3.3 ± 0.3</td>
</tr>
<tr>
<td>6. M18V</td>
<td>AUG</td>
<td>3.0 ± 0.1</td>
<td>0.3 ± 0.04</td>
<td>0.25 ± 0.03</td>
<td>0.75 ± 0.07</td>
<td>3.0 ± 0.2</td>
<td>4 ± 0.8</td>
</tr>
<tr>
<td>6. M18V</td>
<td>UUG</td>
<td>11 ± 0.9</td>
<td>1.2 ± 0.03</td>
<td>0.3 ± 0.01</td>
<td>0.70 ± 0.08</td>
<td>2.4 ± 0.04</td>
<td>4.5 ± 0.8</td>
</tr>
<tr>
<td>8. G31R,G62S</td>
<td>AUG</td>
<td>25 ± 2.4</td>
<td>2.0 ± 0.20</td>
<td>0.30 ± 0.03</td>
<td>0.70 ± 0.10</td>
<td>2.0 ± 0.1</td>
<td>0.15 ± 0.3</td>
</tr>
<tr>
<td>8. G31R,G62S</td>
<td>UUG</td>
<td>18 ± 1.0</td>
<td>0.3 ± 0.03</td>
<td>0.1 ± 0.01</td>
<td>0.90 ± 0.10</td>
<td>9.0 ± 1.0</td>
<td>0.7 ± 0.8</td>
</tr>
<tr>
<td>10. G62S</td>
<td>AUG</td>
<td>18 ± 3.5</td>
<td>3.0 ± 0.40</td>
<td>0.25 ± 0.01</td>
<td>0.75 ± 0.10</td>
<td>3.0 ± 0.05</td>
<td>2.3 ± 0.06</td>
</tr>
<tr>
<td>10. G62S</td>
<td>UUG</td>
<td>25 ± 4.0</td>
<td>2.0 ± 0.03</td>
<td>0.30 ± 0.02</td>
<td>0.70 ± 0.04</td>
<td>1.1 ± 0.04</td>
<td>2.3 ± 0.3</td>
</tr>
<tr>
<td>11. G31R,G62S</td>
<td>AUG</td>
<td>18 ± 2.0</td>
<td>3.0 ± 0.3</td>
<td>0.46 ± 0.04</td>
<td>0.54 ± 0.03</td>
<td>1.1 ± 0.04</td>
<td>1.3 ± 2.1</td>
</tr>
<tr>
<td>12. G31R,G62S</td>
<td>UUG</td>
<td>26 ± 3.0</td>
<td>4.0 ± 0.07</td>
<td>0.30 ± 0.03</td>
<td>0.70 ± 0.10</td>
<td>2.3 ± 0.3</td>
<td>2.1 ± 2.3</td>
</tr>
</tbody>
</table>

*All errors are SE calculated by SD/√n; n = number of experiments.*
scribed above, and plasmid-borne tif11-SE*+SE2*+F131 as the only source of eIF1A. In the TIF5+ strain on glucose medium (where expression of WT eIF5 from P_GAL-TIF5 is repressed), SE*+SE2*+F131 confers a His+ phenotype and elevated UUG::AUG ratio (~0.65), indicating a Sui+ phenotype, and a Slg− phenotype on +His medium (Figure 5C, rows 1–2 and D, columns 1–2), all in agreement with previous results (25). Once again, we found that the tif5-M18V allele confers a dramatic suppression of the strong Sui+ phenotype of tif11-SE*+SE2*+F131, eliminating growth on –His medium (Figure 5C, rows 2–3, –His) and reducing the UUG::AUG ratio to virtually the same low level seen in the isogenic WT TIF11+ strain (Figure 5D, columns 2–3). M18V also partially suppresses the Slg− phenotype on +His medium conferred by SE*+SE2*+F131 (Figure 5C, rows 2–3, +His). The K33E mutation, shown above to be a potent suppressor of G31R/SUI5 (Figure 2) and SUI3–2 (Figure 3B), also efficiently suppresses the Sui+ and Slg− phenotypes of SE*+SE2*+F131, albeit less completely than does M18V (Figure 5C and D, cf. rows/columns 2–4).

In accordance with their inability to suppress the Sui− phenotypes of tif5-G31R (Figure 2) or SUI3–2 (Figure 5A and B), the L61A and T34N mutations fail to suppress the His+/Sui− phenotype and elevated UUG::AUG ratio conferred by SE*+SE2*+F131 (Figure 5C, rows 2, 6, 7, –His; Figure 5D, columns 2, 6, 7); although they can mitigate the Slg− phenotype of this eIF1A mutation (Figure 5C, rows 2, 4, and 7, +His). Furthermore, the G62S mutation confers only partial suppression of the Sui− phenotype of SE*+SE2*+F131 (Figure 5C and D, cf. rows/columns 2 and 5), similar to its incomplete suppression of SUI3–2 (Figure 5A and B).

The ability of the M18V and K33E substitutions to suppress the His+/Sui− phenotypes of the SE*+SE2*+F131 mutation was also observed in the presence of WT eIF5, produced by growing the P_GAL-TIF5 strains on galactose medium (Figure 5E, rows 3, 4 versus 2). The fact that the Ssu− phenotypes of M18V and K33E are partially dominant to TIF5+ implies that the mutant proteins compete with WT eIF5 for association with the scanning PIC and mitigate the ability of the eIF1A-SE*+SE2*+F131 variant to allow aberrant UUG initiation events.

The same trends described above were also observed when we tested the eIF5 mutations for suppression of the Sui− phenotype of sui1–93–97, encoding a cluster of 3 Ala substitutions in helix a2 of eIF1 (26). The TIF5 suppressor alleles were introduced into a sui1Δ P_GAL-TIF5 strain with plasmid-borne sui1–93–97 as the sole source of eIF1. In the TIF5+ strain on glucose medium, the 93–97 mutation in eIF1 confers a His+/Sui− phenotype and increases the UUG::AUG ratio to ~0.19 (Figure 5F, row 1 and Figure 5G, columns 1–2), consistent with our previous results (26). Similar to observations above for Sui− mutations in other factors, (i) the M18V mutation dramatically suppresses the Sui− phenotype of 93–97; (ii) K33E is a potent suppressor but less effective than M18V and (iii) the T34N and L61A mutations confer no detectable suppression of the Sui− phenotype of 93–97 (Figure 5F and G). Remarkably, G62S is completely ineffective in reducing the Sui− phenotype of 93–97 (Figures 5F, row 4 and 5G, column 5), in sharp contrast to its full suppression of tif5-G31R (Figure 2).

**DISCUSSION**

eIF5 promotes initiation accuracy by stimulating P1 release and enhancing the closed PIC conformation at AUG codons

In this study, we obtained strong genetic and biochemical evidence that eIF5 controls start codon recognition not merely by functioning as a GAP but also by regulating gated P1 release from eIF2-GDP-Pi. Previous work on the eIF5-G31R variant (SUI5 product) suggested that it enhances UUG initiation by elevating the GAP function of eIF5 (11). We subsequently determined that P1 release is accelerated more strongly than GTP hydrolysis by AUG recognition, and that P1 release is blocked until eIF1 dissociates on start codon recognition (10). In this view, it is less obvious that a simple increase in the rate of GTP hydrolysis evoked by eIF5-G31R would accelerate P1 release preferentially at near-cognates to increase UUG initiation. Indeed, we discovered here that G31R alters the coupling between start codon recognition and P1 release to accelerate release at UUG codons while reducing it at AUG codons. This discovery mirrors our previous findings that eIF5-G31R stabilizes the closed state at UUG while destabilizing it at AUG codons, based on results from an assay (eIF1A dissociation kinetics) in which GTP hydrolysis does not occur (27). Both effects of eIF5-G31R on reconstituted PICs provide a satisfying explanation for its ability to increase the UUG::AUG initiation ratio in vivo (Sui− phenotype). They also suggest that the shift from the open to closed state of the PIC precedes and is required for P1 release, consistent with previous results (3). Interestingly, while this study was underway, we found that eIF5-G31R accelerates eIF1 dissociation from the PIC at AUG codons but does not reduce the eIF1 dissociation rate at AUG codons (28), ostensibly at odds with our findings here on P1 release for PICs reconstituted with mRNA(AUG). Presumably, G31R blocks rapid P1 release at AUG codons following eIF1 dissociation; and one possibility is that it impedes the functional interaction between eIF5-NTD and eIF1A-CTT shown recently to be necessary for P1 release following eIF1 dissociation (3).

Evidence supporting the physiological relevance of the dual effects of eIF5-G31R on P1 release and rearrangement to the closed PIC conformation was obtained by examining second-site suppressors in eIF5 that mitigate the Sui+ phenotype of SUI5. We established that two eIF5 substitutions, M18V and G62S, very efficiently suppress the dominant Sui+ phenotype of G31R; and that G62S, but not M18V, also suppresses the recessive lethality of G31R. When present as the only substitution in eIF5, M18V also efficiently suppresses the Sui− phenotypes of mutations in eIF2β, eIF1A and eIF1, but this was not true for eIF5-G62S. These marked differences in the genetic properties of M18V and G62S resonate with results of our in vitro analyses, which revealed distinctly different effects of M18V and G62S on GTP hydrolysis/P1 release and the transition from open to closed PIC conformations.

Consistent with the proximity of Met-18 to Arg-15, a key residue of the eIF5 GAP domain, combining M18V with G31R reduces the rates of both GTP hydrolysis and P1 release and partially reverses the aberrant effect of G31R in provoking more rapid P1 release at UUG versus AUG.
Figure 5. TIF5 suppressors confer allele-specific suppression of Sui− mutations in eIF2β, eIF1A and eIF1. (A) Slg− and His+/Sui− phenotypes of derivatives of his4-301 strain ASY100 harboring the indicated TIF5 alleles on LEU2 plasmid and either YCPSU3-2 plasmid harboring SU3-2 (rows 2–7) or empty vector (row 1) were determined by spotting serial 10-fold dilutions on SC medium lacking leucine and tryptophan (SC-LW) supplemented with 0.3 mM His (+His) or 0.0003 mM His (−His) and incubated for 3d (−His) or 6d (+His) at 30°C. (B) Strains described in (A) harboring the AUG or UUG HIS4-lacZ reporters were analyzed as in Figure 2C. (C) Derivatives of his4-301 tif11Δ PGAL-TIF5 strain PMY17 harboring a TRP1 plasmid with WT TIF11 (pAS5-142) (lane 1) or tif11-SE1*,SE2*+F131 (pAS5-130) (Lanes 2–7) were transformed with LEU2 plasmids containing the indicated TIF5 alleles, and Slg− and His+/Sui− phenotypes were determined as in (A). (D) Strains described in (C) harboring the AUG or UUG HIS4-lacZ reporters were analyzed as in (B). (E) Dominant His+/Sui− and Slg− phenotypes of the strains in (C) were analyzed by spotting serial 10-fold dilutions on SC medium containing galactose and lacking tryptophan and leucine supplemented with 0.3 mM His (Gal + His) or 0.0003 mM His (Gal −His) and incubating for 3d (Gal + His) or 6d (Gal −His) at 30°C. (F) Slg− and His+/Sui− phenotypes were determined for derivatives of his4-301 sui1Δ PGAL-TIF5 strain PMY01 harboring sui1-93-97 on a TRP1 plasmid and LEU2 plasmids containing the indicated TIF5 alleles were determined as in (C). (G) Strains described in (F) harboring the AUG or UUG HIS4-lacZ reporters were analyzed as described in (D). For panels A, C and F, images have been cropped from results obtained from different plates examined in parallel in the same experiments.
codons. This last effect is consistent with the reduction in the UUG:AUG ratio (Ssu− phenotype) produced by M18V in the eIF5-G31R,M18V double mutant. By contrast, M18V had relatively little impact on the ability of G31R to reverse the differential effects of AUG and UUG on stability of the closed PIC conformation, as revealed by eIF1A dissociation kinetics. Thus, we propose that the principle consequence of M18V is to impair the ability of Arg15 to function as an arginine finger, reducing GTP hydrolysis and subsequent P1 release. This proposal is supported by our finding that M18V on its own dramatically reduces the rate of the GTP hydrolysis phase of the GTPase reactions at both AUG and UUG codons, as well as the eIF5-dependent stimulation of GTP hydrolysis by isolated TCs. The fact that G31R,M18V is recessive-lethal whereas M18V alone is viable can be explained by proposing that combining the aberrant destabilization of the closed PIC conformation at AUGs conferred by G31R with the impairment of GTP hydrolysis/P1 release by M18V evokes a lethal reduction in bulk translation initiation.

The G62S substitution differs from M18V in suppressing both the lethality and Sui− phenotypes of the G31R mutation in eIF5. The ability of G62S to suppress the Sui− phenotype of G31R can be understood from our biochemical findings that (i) it overcomes the effect of G31R of elevating P1 release at UUG codons and depressing the reaction at AUG codons and (ii) it mitigates the effect of G31R of stabilizing the closed conformation of the PIC at UUG codons. This dual effect of G62S in restoring more nearly WT differential rates of P1 release and closed complex occupancies at both AUG and UUG codons also helps to explain its ability to suppress the lethality of G31R. Thus, compared to the dramatic effect of G31R,M18V in reducing GTP hydrolysis/P1 release rates at both start codons, G62S provokes a more nuanced effect on the kinetics of P1 release in the G31R,G62S variant that moves the system closer to

![Figure 6](image-url)
WT behavior. Accordingly, we envision that G62S alters the regulatory mechanism that couples P1 release to the quality of the codon-anticodon helix in the P site, rather than directly altering the catalytic function of the putative Arg finger of the GAP domain.

M18V is the most effective Ssu− mutation described thus far, in completely eliminating the increased UUG:AUG initiation ratio in cells harboring Sui− mutations in eIF1 (sui−/−,93–97), eIF1α (tif11−/−,SE1∗,SE2∗+F131) or eIF2β (SUI3−2). The following considerations suggest that the broad Ssu− characteristic of M18V derives from its strong reduction in rate of GTP hydrolysis and P1 release at UUG codons. In addition to eIF1 dissociation, P1 release also requires movement of the eIF5-NTD and eIF1A-CTT closer to one another in the PIC (3). The fact that overexpressing WT eIF1 suppresses UUG initiation in all Sui− mutants tested (2), makes it likely that P1 release at UUGs can be prevented in Sui− mutants by driving the rapid re-association of eIF1 with its 40S binding site in the open PIC conformation after its initial release on UUG recognition. Through a related mechanism, by greatly reducing the rate of GTP hydrolysis/P1 release, eIF5-M18V could increase the probability that scanning can resume at UUG codons by allowing more time for re-association of eIF1 with the PIC. Delaying P1 release in this way would allow eIF5-M18V to suppress any Sui− mutation that shifts the balance toward the closed/P1N state with attendant release of eIF1. Indeed, this property has been described for sui−/− (26), tif11−/−,SE1∗,SE2∗+ (25) and SUI3−2 (28), consistent with the strong suppression of all three Sui− mutations by eIF5-M18V. In this view, G62S is inferior to M18V in suppressing these Sui− mutations because it has no intrinsic effect on P1 release and, hence, does not delay this reaction sufficiently to allow eIF1 re-association and resumption of scanning at UUG codons.

It was surprising to find that the T34N and L61A substitutions in eIF5 suppress the recessive lethality of the eIF5-G31R variant but are generally ineffective suppressors of the Sui− phenotypes of eIF5-G31R and the other Sui− mutations we analyzed. These findings likely indicate that the lethality of SUI5/G31R reflects the compound effects of a reduced efficiency of AUG initiation and elevated UUG initiation and that restoring AUG initiation is sufficient to rescue viability. One possibility is that T34N and L61A mitigate the defect in AUG recognition conferred by G31R but produce an equally stimulatory effect on UUG initiation, leaving the ratio of UUG:AUG initiation unaltered from that observed in the G31R/SUI5 single mutant.

Molecular implications of Ssu− mutations for eIF5’s multiple functions in start codon recognition

Our finding that the eIF5-M18V substitution strongly impairs GTP hydrolysis and P1 release in the PIC fits with its location only three residues from Arg-15 in the NTT of eIF5 (Figure 6A and B). Arg fingers are usually flanked by hydrophobic residues that stabilize the Arg finger loop and, indeed, R15 is flanked by Phe and Tyr residues: F13 Y14 R15 Y16 K17 M18 (7 and references therein). As M18V replaces one flanking hydrophobic residue with another, it would not necessarily perturb hypothetical packing of the Arg finger loop with the core of the GAP domain, but perhaps the Val substitution disturbs the orientation of Arg-15 in a manner that reduces its ability to stimulate GTP hydrolysis.

K33E is second only to M18V in its ability to reduce the UUG:AUG initiation ratios conferred by the panel of Sui− mutations we examined in other factors (Figure 5B, D and G), although it differs from M18V in also suppressing the lethality of G31R. Interestingly, the K33A substitution in rat eIF5 impairs its ability to replace endogenous eIF5 in yeast cells and reduces GTP hydrolysis in a model GAP assay (8). It has been suggested that K33 plays the role of the secondary stabilizing Lys or Arg described in other GAPS, which is consistent with its location in the β1−loop−β2 also containing the SUI5/G31R substitution (Figure 6A and B) (7). It seems plausible that K33E reduces GAP function and P1 release, albeit not as severely as M18V, which enables it to suppress multiple Sui− mutations by the mechanism proposed above for M18V, of delaying P1 release to allow time for eIF1 re-association and resumption of scanning at UUG codons. The residue substituted in T34N is immediately adjacent to K33 in β2. We suggested above that T34N stimulates AUG and UUG initiation equally when combined with G31R; but on its own, T34N enhances UUG initiation to a greater extent and confers a Sui− phenotype. These results further implicate the β1−loop−β2, modified by G31R, K33E and T34N, in regulating GTP hydrolysis and P1 release.

We argued above that, when combined with G31R, the G62S substitution perturbs the regulatory mechanism coupling P1 release to the quality of the codon-anticodon helix rather than impairing the catalytic function of Arg-15. G62, and the adjacent residue altered by the suppressor substitution L61, map at the end of helix α2 and beginning of the [α2−β3] loop, and are located on the opposite face of the eIF5 NTD from the NTT and Arg-15 (7) (Figure 6C and D). Considering that G62S also mitigates the effect of G31R in stabilizing the closed complex at UUG, we suggest that α2 and the [α2−β3] loop function in coupling codon-anticodon pairing to stabilization of the closed complex in addition to regulating P1 release. Because eIF1A dissociation kinetics are measured using TC assembled with non-hydrolyzable Guanosine 5′-[β,γ-imido]triphosphate (GDPNP), the effect of G62S in destabilizing the closed conformation of the PIC is unlikely to be secondary to its effects on P1 release; however, the decrease in P1 release could be a consequence of destabilization of the closed complex. An interesting possibility is that eIF5 residues in α2 or the [α2−β3] loop enhance the functional interaction of the eIF5 NTD with the eIF1A CTT required to stabilize the closed/P1N state and trigger P1 release (3).

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGMENT

We thank Tom Donahue for gifts of Ssu− strains and sharing unpublished information, and Tom Dever for many helpful discussions and suggestions.
FUNDING

Intramural Program of the National Institutes of Health [in part to A.G.H. and J.R.L.]; National Institutes of Health Grant [GM62128] [formerly to J.R.L.]; Department of Science and Technology, Government of India Grant [Int/NZ/P-2/13] [to A.K.S.]. Funding for open access charge: Intramural Program of the National Institutes of Health [to A.G.H. and J.R.L.]; National Institutes of Health Grant [GM62128] [formerly to J.R.L.]; Department of Science and Technology, Government of India Grant [Int/NZ/P-2/13] [to A.K.S.].

Conflict of interest statement. None declared.

REFERENCES